Nestle SA (NESN.VX) said Monday it sees no reason to renegotiate deal terms on eyecare company Alcon Inc. (ACL) with Swiss drugmaker Novartis AG (NVS).

"We firmly believe the business continues to deliver excellent results and therefore there is no need to renegotiate any contractual terms of the agreement," James Singh said at an investor event.

Singh is Nestle's head of finance and control.

Company Web site: www.nestle.com

-By Katharina Bart, Dow Jones Newswires; +41 43 443 8043; katharina.bart@dowjones.com